Who Owns Karyopharm Therapeutics Stock?
NASDAQ: KPTIHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 97.03%
- Institutions (% of float)
- 101.78%
- Held by insiders
- 4.67%
- Institutional holders
- 136
- Institutions 95.3%
- Insiders 4.7%
- Public and other 0.0%
Who owns Karyopharm Therapeutics stock?
Institutional investors own about 97.0% of Karyopharm Therapeutics's shares, spread across 136 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 4.67% of KPTI.
The largest institutional holders are RA Capital Management, L.P. (8.45%), Adage Capital Partners GP L.L.C. (6.71%) and Acorn Capital Advisors, LLC (6.69%). Together, the top 10 institutions control 53.4% of shares outstanding. In their latest filings, 7 of the top 10 institutions increased their KPTI positions and 2 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of KPTI
| Institution | Shares | % Held | Change |
|---|---|---|---|
| RA Capital Management, L.P. | 1.92M | 8.45% | 0.0% |
| Adage Capital Partners GP L.L.C. | 1.52M | 6.71% | -15.8% |
| Acorn Capital Advisors, LLC | 1.52M | 6.69% | +427.4% |
| Goldman Sachs Group Inc | 1.42M | 6.28% | +50.4% |
| Blackrock Inc. | 1.42M | 6.26% | +479.3% |
| Vanguard Capital Management LLC | 958.98K | 4.23% | +29.6% |
| Catalio Capital Management, LP | 940.86K | 4.15% | +4.8% |
| Avidity Partners Management, LP | 924.49K | 4.08% | +99.3% |
| T. Rowe Price Investment Management, Inc. | 786.31K | 3.47% | -49.0% |
| Two Sigma Investments, LP | 695.26K | 3.07% | +359.7% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of KPTI
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 677.73K | 2.99% |
| iShares Trust-iShares Russell 2000 ETF | 482.93K | 2.13% |
| T. Rowe Price Small-Cap Value Fund, Inc. | 435.07K | 1.92% |
| TR PRICE-Price (T.Rowe) U.S. Small-Cap Value Equity Trust | 312.41K | 1.38% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 263.08K | 1.16% |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 216.01K | 0.95% |
| Fidelity Covington Trust-Fidelity Enhanced Small Cap Core ETF | 174.36K | 0.77% |
| iShares Trust-iShares Russell 2000 Value ETF | 151.90K | 0.67% |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 110.40K | 0.49% |
| iShares Trust-iShares Micro-Cap ETF | 66.50K | 0.29% |
Frequently asked questions
Who is the largest shareholder of Karyopharm Therapeutics?
RA Capital Management, L.P. is the largest institutional shareholder of KPTI, owning 8.45% of shares outstanding (1.92M shares) as of its latest 13F filing.
What percentage of Karyopharm Therapeutics is owned by institutions?
Institutions own about 97.0% of KPTI shares and 101.8% of the public float.
How much of Karyopharm Therapeutics do insiders own?
Insiders, such as officers and directors, own about 4.67% of KPTI shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.